Navigation Links
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
Date:6/17/2008

BELLEVUE, WA, June 17 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced enrollment of the first patient in a Phase 1 trial of PX-866 in patients with advanced solid tumors. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), an important cell survival signaling pathway.

"PX-866 is a potent inhibitor of PI-3K, a component of a critical pathway that is activated in many types of cancer, leading to tumor growth and survival," said Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of Oncothyreon. "We believe that the mechanism of action of PX-866, which irreversibly inhibits PI-3K, will have pharmacokinetic and pharmacodynamic advantages that will distinguish PX-866 in the competitive field of PI-3K inhibitors."

The Phase 1 trial is expected to enroll up to 63 patients with advanced metastatic cancer who have failed or are intolerant of standard therapy. Patients will receive PX-866 orally once per day on days 1 through 5 and 8 through 12 during a four-week treatment cycle. Primary objectives of the study include establishment of a maximum tolerated dose, evaluation of safety, and analysis of the pharmacodynamic and pharmacokinetic profiles of PX-866.

"The start of the PX-866 trial represents a significant milestone for Oncothyreon, as we now have three active clinical programs underway for our promising small molecule inhibitors," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "Together with our therapeutic vaccine programs, we have successfully established a broad and diverse oncology pipeline targeting multiple cancer indications with substantial unmet medical need, and we look forward to sharing the ongoing pro
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Oncothyreon highlights corporate and clinical objectives for 2008
3. Oncothyreon to present at BIO CEO & Investor Conference
4. Oncothyreon launches new corporate website
5. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
6. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon announces issuance of patent for PX-867
10. Oncothyreon announces effectiveness of shelf registration statement
11. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 Space ... Human exploration of space requires astronauts to maintain consistently ... and success, and prevent potential errors and accidents. Despite ... is known about how cognition is affected by prolonged ... Now, Penn Medicine researchers are poised to ...
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2
... Silence Therapeutics plc (AIM: SLN), a leading international ... partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant ... worldwide license to develop and commercialise QPI-1002, a p53 ... Quark is currently conducting a Phase II ...
... 19 US Oncology, Inc., the nation,s ... than two decades it has played a role in ... the US Food and Drug Administration (FDA). ... http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) Tasigna ® (nilotinib) capsules, ...
... Researchers have developed an improved coating technique that could ... patients, own bone. The stronger connection -- created by ... growth -- could allow the implants to last longer. ... engineered protein that mimics the body,s own cell-adhesion material ...
Cached Biology Technology:Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 3US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 4Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 2Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 3
(Date:11/15/2014)... Nov. 13, 2014  While we may still be a ... used in "Star Trek" to gain instant access to all ... work with smartphones and tablets for monitoring and measuring our ... world. This may seem a tad Orwellian to some, but ... some of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Migration negation 2Migration negation 3
... in the open ocean may force scientists to rethink ... ocean ecosystems. A research team led by Jonathan Zehr, ... Santa Cruz, characterized the new microbe by analyzing its ... to grow it in the laboratory. Zehr ...
... professor at The University of Texas at Austin, will ... on Greenhouse Gas Control Technologies that examines a unique ... of CO2 escaping via buoyancy. When: Nov. 19, ... 2500 Calvert St. NW, in Washington, D.C. The research ...
... University Biologist Richard Bonneau has been named one of ... Discover magazine. Bonneau, 33, is an assistant ... and Systems Biology and the university,s Courant Institute of ... appears in Discover,s December issue. Bonneau,s ...
Cached Biology News:Mysterious microbe may play important role in ocean ecology 2Mysterious microbe may play important role in ocean ecology 3Engineer to present leak-proof method for carbon dioxide storage at international conference 2NYU biologist Bonneau named among 20 "visionary" scientists under 40 by Discover magazine 2
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: